– Median Treatment Duration of 15 Months Observed in Non-Enhancing Glioma with 13 Patients Remaining on
Treatment Provides Evidence of Prolonged Disease Control –
– Favorable Safety Profile at 10 mg and 50 mg, Doses Under Evaluation in Ongoing Glioma Perioperative Study
–
NEW ORLEANS, Nov. 16, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular
metabolism to treat cancer and rare genetic diseases, today presented updated data from the ongoing Phase 1 study evaluating single
agent AG-881 in advanced glioma. The data were featured in an oral presentation at the Society for Neuro-Oncology (SNO) Annual
Meeting in New Orleans. AG-881 is an investigational, oral, selective, potent inhibitor of the mutant isocitrate dehydrogenase-1
(IDH1) and IDH2 enzymes and was designed for enhanced brain penetrance for development in IDH-mutant glioma.
“With additional follow-up, the AG-881 Phase 1 dose-escalation data continue to show a favorable safety profile at the doses
selected for the perioperative study. Longer treatment duration and a reduction in tumor growth rates are encouraging signs of
clinical activity in low-grade glioma,” said Ingo Mellinghoff, M.D., Memorial Sloan Kettering Cancer Center, an investigator for
the study. “Ultimately, use of an IDH inhibitor in this difficult-to-treat disease has the potential to improve the current
treatment paradigm by delaying the multiple rounds of surgery, radiation and chemotherapy that many patients endure.”
“With no curative or approved targeted therapies and a high frequency of IDH1 mutations in low-grade glioma, we are committed to
advancing one of our IDH inhibitors to a registrational study in this disease,” said Chris Bowden, M.D., chief medical officer at
Agios. “We are continuing to collect clinical data for both ivosidenib and AG-881, along with feedback from regulators and the
neuro-oncology community, to make an internal decision on our glioma pivotal strategy by the end of this year.”
Study Status
AG-881 is being evaluated as a single agent in an ongoing Phase 1 dose-escalation trial in IDH1/2 mutant advanced solid tumors,
including glioma. Enrollment was completed in June 2017. Dose escalation data as of March 29, 2018 were presented at the 2018
American Society of Clinical Oncology (ASCO) Annual Meeting. As of the updated July 20, 2018 data cut-off, study design, enrollment
and baseline characteristics of the 52 glioma patients remain unchanged, as reported below.
- Forty-eight percent of patients (n=25) had World Health Organization (WHO) classified Grade 2 tumors, 42% (n=22) had Grade 3
tumors, 8% (n=4) had Grade 4 tumors and 2% (n=1) was unknown.
- The median age of these patients is 42.5 years (ranging from 16-73 years).
- Patients received a median of two prior systemic therapies (ranging from one to six).
- Seventy-three percent of patients (n=38) had previously received temozolomide and 58% percent (n=30) had previously
received radiotherapy.
- Patients received daily doses of AG-881 ranging from 10 mg to 300 mg.
Updated safety and efficacy data on the 52 patients with enhancing and non-enhancing glioma, including an exploratory tumor
volume growth rate analysis, are reported below.
- Fourteen patients remain on treatment, including 13 patients with non-enhancing disease.
- Of the 38 patients who discontinued treatment, 76.3% (n=29) discontinued for disease progression and 5.2% (n=2) discontinued
due to an AE.
- The median treatment duration was 6.3 months (ranging from 0.2-32 months) for all glioma patients, 15 months (ranging from
1-32 months) for non-enhancing glioma and 3.25 months (ranging from 0.2- 32 months) for patients with enhancing disease.
- Thirty-seven percent of patients (n=19, including 15 patients with non-enhancing disease) remained on treatment for ?1
year.
Safety Data
The safety analysis conducted for all 52 glioma patients as of the data cut-off demonstrated that AG-881 continues to have a
favorable safety profile at dose levels below 100 mg.
- The majority of adverse events (AEs) reported by investigators were mild to moderate, with the most common (>30%) being
increases in alanine aminotransferase (ALT) (n=23), increases in aspartate aminotransferase (AST) (n=21), headache (n=19) and
fatigue (n=17).
- Grade 3 or higher AEs were observed in 19% of all patients (n=10). AEs occurring in more than one patient included seizure
(n=4), ALT increases (n=3) and AST increases (n=2).
- As reported in June, dose limiting toxicities (DLTs) of Grade 2 or higher elevated transaminases occurred in five glioma
patients at the higher dose levels (?100 mg) and resolved to Grade ?1 with dose modification or discontinuation. There were no
new DLTs reported as of the new data cut-off or any treatment-related on-treatment deaths.
- Doses of 10 mg and 50 mg are under evaluation in an ongoing perioperative study in non-enhancing glioma.
Efficacy Data
Efficacy data from the 52 glioma patients (22 with non-enhancing and 30 with enhancing disease) as of the data cut-off
showed:
- One patient with non-enhancing disease and a 1p19q co-deletion had a confirmed / sustained partial response according to the
investigator by Response Assessment in Neuro-Oncology for low grade glioma (RANO-LGG) and remains on treatment.
- One patient with non-enhancing disease and a 1p19q co-deletion had a confirmed / sustained minor response according to the
investigator by RANO-LGG and remains on treatment.
- Sixty-nine percent of patients (n=36) had a best response of stable disease, including 82% (n=18) patients with non-enhancing
disease.
- For non-enhancing patients with available data (n=18), the average volumetric six-month tumor growth was 6.8% following
treatment with AG-881; pre-treatment volumetric growth rates were not available for these patients. For a similar population of
IDHm low-grade glioma patients in the ongoing Natural History study, the average six-month volumetric growth prior to treatment
was 24.5%.
Ongoing Glioma Perioperative Study Presented in Trials in Progress Poster
A perioperative 'window' trial with ivosidenib and AG-881 (10 mg and 50 mg) in up to 45 IDH1m non-enhancing low-grade glioma
patients is ongoing and being presented today as part of a trials in progress poster. The goal of the trial is to confirm CNS
penetrance and tumor 2-HG suppression of ivosidenib and AG-881 as part of the strategy to finalize internal pivotal development
plans by year-end 2018.
About Glioma
Glioma presents in varying degrees of tumor aggressiveness, ranging from slower growing (low-grade glioma) to rapidly progressing
(high-grade glioma-Glioblastoma Multiforme). Common symptoms include seizures, memory disturbance, sensory impairment and
neurologic deficits. The long-term prognosis is poor with a five-year survival rate of 33 percent. Approximately 11,000 low-grade
glioma patients are diagnosed annually in the U.S. and EU and approximately 80 percent have an IDH1 mutation.
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through
scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both
therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in
clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our
knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.
Such forward-looking statements include those regarding the potential benefits of AG-881; Agios’s plans for future clinical
development of AG-881; and the potential benefit of Agios’s strategic plans and focus. The words “could,” “expect,” “intend,”
“may,” “path,” “plan,” “potential,” “strategy,” “will,” and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous
important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios' current
expectations and beliefs. For example, there can be no guarantee that any product candidate Agios or its collaborator, Celgene, is
developing will successfully commence or complete necessary preclinical and clinical development phases, or that development of any
of Agios' product candidates will successfully continue. There can be no guarantee that any positive developments in Agios'
business will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this
press release could also be affected by risks and uncertainties relating to a number of other important factors, including: Agios'
results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from
ongoing and future studies; the content and timing of decisions made by the U.S. FDA and other regulatory authorities,
investigational review boards at clinical trial sites and publication review bodies; Agios' ability to obtain and maintain
requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures;
competitive factors; Agios' ability to obtain, maintain and enforce patent and other intellectual property protection for any
product candidates it is developing; Agios' ability to maintain key collaborations, such as its agreements with Celgene and CStone
Pharmaceuticals; and general economic and market conditions. These and other risks are described in greater detail under the
caption "Risk Factors" included in Agios’ public filings with the Securities and Exchange Commission. Any forward-looking
statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update
any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contacts
Investors:
Renee Leck, 617-649-8299
Associate Director, Investor Relations
Renee.Leck@agios.com
Media:
Holly Manning, 617-844-6630
Associate Director, Corporate Communications
Holly.Manning@agios.com
